Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy’s Laboratories Limited Under Fasting Conditions

Overview

The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Zonisamide 100 mg Capsule to that of Zonegran® 100 mg Capsule after a single, one-capsule dose in fasted subjects.

Full Title of Study: “A Randomized. Single-Dose, Two-Way Crossover Relative Bioavailability Study of Zonisamide Formulations in Fasted Normal, Healthy Men and Women”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2005

Detailed Description

This was an open label, randomized, balanced, single dose, two-period, two-treatment, two-sequence crossover study, performed under fasting conditions. Subjects were confined to the SFBC Clinical Research Facility from at least 10 hours prior to drug administration, until after the 24-hour post-dose blood draw, in each period. The treatment phases were separated by a washout period of 28 days.

Interventions

  • Drug: Zonisamide
    • Zonisamide capsules 100 mg
  • Drug: Zonegran
    • Zonegran Capsules 100 mg of EISAI INC

Arms, Groups and Cohorts

  • Experimental: Zonisamide
    • Zonisamide Capsules 100 mg of Dr.Reddy’s laboratories Limited
  • Active Comparator: Zonegran
    • Zonegran Capsules 100 mg of EISAI INC

Clinical Trial Outcome Measures

Primary Measures

  • Bioequivalence on Cmax,AUC and Tmax Parameters
    • Time Frame: 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • Is the individual a healthy, normal adult man or non-child bearing potential woman who volunteers to participate? – Is s/he at least 18 years of age? – Is his/her BMI between 19 and 30, inclusive? – Is s/he considered reliable and capable of understanding his/her responsibility and role in the study? – Has s/he provided written informed consent? Exclusion Criteria:

  • Does the individual have a history of allergy or hypersensitivity to zonisamide or sulfonamides? – Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? – Does s/he have serious psychological illness? – Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse? – Does s/he have a positive urine drug screen, or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test? – Has s/he consumed grapefruit or grapefruit juice during the 7-day period preceding study initiation? – Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken? – Has s/he used any prescription drug during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation? – Is s/he unable to refrain from the use of all concomitant medications during the study? – Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation? – Has s/he donated plasma during the two week period preceding study initiation? – Has s/he received an investigational drug during the 30 day Period preceding study initiation?

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Dr. Reddy’s Laboratories Limited
  • Provider of Information About this Clinical Study
    • Vice president-Research & Development, Dr. Reddy’s Laboratories Limited
  • Overall Official(s)
    • Antonio R Pizarro, M.D, Principal Investigator, SFBC Ft. Myers, Inc

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.